Table 1.
Women (n = 159) | Men (n = 249) | Lost to follow-up (n = 69) | p** | |
---|---|---|---|---|
Age, mean years (SD) |
62.3 (6.7) |
64.2 (7.0) |
66.8 (5.9) |
<0.01 |
FFMI, mean kg/m2 (SD) |
14.8 (2.4) |
18.4 (3.0) |
- |
|
FMI, mean kg/m2 (SD) |
10.1 (4.3) |
7.3 (2.5) |
- |
|
% cachectic* |
31.0 |
27.5 |
37.3 |
0.10 |
Smoking habits, n(%) |
|
|
|
0.32 |
ex |
88 (55.3) |
144 (57.8) |
43 (62.3) |
|
current |
71 (44.7) |
105 (42.2) |
26 (37.7) |
|
GOLD stage |
|
|
|
<0.01 |
II |
82 (51.6) |
111 (44.6) |
22 (31.9) |
|
III |
66 (41.5) |
105 (42.2) |
31 (44.9) |
|
IV |
11 (6.9) |
33 (13.2) |
16 (23.2) |
|
Hypoxemia, n(%) |
|
|
|
<0.01 |
PaO2 > 9 kPa |
84 (61.3) |
150 (64.4) |
26 (44.1) |
|
PaO2 8–9 kPa |
33 (24.1) |
56 (24.0) |
17 (28.8) |
|
PaO2 < 8 kPa |
20 (14.6) |
27 (11.6) |
16 (27.1) |
|
Exacerbations last year, n(%) |
|
|
|
0.01 |
0-1 |
126 (79.3) |
214 (85.9) |
50 (72.5) |
|
2+ |
33 (20.7) |
35 (14.1) |
19 (27.5) |
|
Charlson Comorbidity Index |
|
|
|
<0.01 |
1 |
101 (63.5) |
130 (52.2) |
30 (43.5) |
|
2 |
40 (25.2) |
59 (23.7) |
15 (21.7) |
|
3 |
13 (8.2) |
36 (14.5) |
12 (17.4) |
|
4+ |
5 (3.1) |
24 (9.6) |
12 (17.4) |
|
Use of inhaled steroids |
|
|
|
0.19 |
No |
40 (25.2) |
88 (35.3) |
17 (24.6) |
|
Yes |
119 (74.8) |
161 (64.7) |
52 (75.4) |
|
Use of long-acting beta2 agonists |
|
|
|
0.07 |
No |
33 (20.8) |
80 (32.1) |
13 (18.8) |
|
Yes |
126 (79.2) |
169 (67.9) |
56 (81.2) |
|
Use of theophyllin |
|
|
|
0.02 |
No |
144 (90.6) |
228 (91.6) |
58 (84.1) |
|
Yes |
15 (9.4) |
21 (8.4) |
11 (15.9) |
|
CRP, mean ug/mL (SD) |
2.4 (3.1) |
2.4 (2.7) |
2.5 (2.5) |
0.35 |
TNF-α mean pg/mL (SD) |
1.8 (3.4) |
1.8 (3.3) |
1.2 (2.5) |
0.12 |
IL-1ß, mean pg/mL (SD) |
0.8 (2.0) |
1.0 (2.2) |
1.0 (2.1) |
0.77 |
IL-6, mean pg/mL (SD) | 2.2 (6.8) | 2.2 (5.5) | 1.4 (2.7) | 0.32 |
*defined as FFMI < 14 kg/m2 for women and <17 kg/m2 for men.
**for difference between baseline and lost to follow up; chi square for categorical variables and Kruskal Wallis test for continuous variables.